What is Emideltide?
Emideltide, better known as delta sleep-inducing peptide (DSIP), is a naturally occurring neuropeptide first described decades ago and studied for sleep and stress. It is not an FDA-approved drug.
What the evidence shows
Human research on DSIP dates back several decades and has produced inconsistent results. By modern standards it is not established as a safe and effective treatment for insomnia, opioid withdrawal, or any other condition.
Is it legal?
Emideltide is not FDA-approved. In April 2026 it was removed from FDA Category 2 but not moved to the approved Category 1 list, so legal compounding is not authorized; the PCAC reviews it on July 24, 2026.
Will Emideltide become legal in 2026?+
Is “research-grade” Emideltide the same as a medicine?+
Primary sources: FDA 503A interim list; FDA-reviewed uses per PCAC agenda · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. Emideltide is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.